Safety and Efficacy of Inpatient Infliximab Rescue Therapy for Acute Crohn's Disease Flares

• Published in: The American surgeon Vol. 90; no. 6; p. 1591
• Main Authors: Whitlock, Ashlyn E, Arndt, Kevin R, Zakopoulos, Iordanis, Wong, Daniel J, Kaul, Sumedh, Feuerstein, Joseph, Crowell, Kristen T, Messaris, Evangelos
• Format: Journal Article
• Language: English
• Published: United States 01.06.2024
• Subjects: Acute Disease; Adult; Crohn Disease - drug therapy; Female; Gastrointestinal Agents - therapeutic use; Humans; Infliximab - therapeutic use; Male; Middle Aged; Postoperative Complications - drug therapy; Retrospective Studies; Symptom Flare Up; Treatment Outcome; Young Adult; Crohn’s flare; rescue therapy; inflammatory bowel disease
• ISSN: 1555-9823
• DOI: 10.1177/00031348241246160

Describe the safety, complications, and need for urgent surgery in patients requiring inpatient rescue infliximab for acute Crohn's disease (CD) flare. Infliximab is increasingly used for patients hospitalized with acute severe ulcerative colitis as rescue therapy; however, optimal management for patients hospitalized for CD flares remains unclear. A single-institution retrospective study of patients aged 18+ admitted from 2008 to 2020 with acute Crohn's flare requiring induction of rescue infliximab therapy. Outcomes included postoperative and medication-related complications and need for urgent surgery. 52 patients were included in analysis; 8% required surgery on index admission, and 19% required surgery within 90 days of infliximab. Postoperative complications included 1 anastomotic leak, 3 superficial wound infections, 3 prolonged ileus, and 1 urinary infection. There were no adverse reactions to infliximab infusion, and medical complication rates were low. Patients with penetrating disease were more likely to undergo surgery within 90 days of infliximab (43% vs 8%; = .01). Mean LOS was longer for patients undergoing surgery within 90 days of therapy compared to those who did not (13.4 vs 8.3 days, = .04). Inpatient rescue infliximab is safe for treating acute Crohn's disease flare in addition to standard steroid therapy. The majority of patients hospitalized with Crohn's flare requiring rescue infliximab avoided surgery with low postoperative and medication-related complications. More research is needed to clarify the optimal rescue infliximab therapy dosage.